Physician‑Guided · HIPAA Compliant · Discreetly Delivered Nationwide
Most Efficacious Approved Weight Management · Dual GIP/GLP-1
Zepbound®
Up to 22.5% average body weight reduction in Phase 3 trials. Zepbound® represents the most efficacious FDA-approved pharmacological treatment for obesity to date — powered by dual GIP and GLP-1 receptor activation.
You will be directed to our licensed telehealth partner to complete your consultation.
Zepbound® (tirzepatide) is the first dual GIP and GLP-1 receptor agonist approved by the FDA specifically for chronic weight management in adults with obesity or overweight with a weight-related condition. It contains the same active molecule as Mounjaro® — tirzepatide — but carries a distinct FDA indication for weight management rather than diabetes. Clinical trial data from the SURMOUNT program has established Zepbound® as the most efficacious approved anti-obesity pharmacotherapy to date. Through The Project Rx and our licensed telehealth partner, eligible adults can access a comprehensive consultation with a licensed provider to evaluate whether Zepbound® is appropriate for their long-term weight management goals.
What Is Zepbound®?
Zepbound® is the brand name for tirzepatide 2.5 mg–15 mg, a once-weekly injectable dual GIP/GLP-1 receptor agonist developed by Eli Lilly and Company. The FDA approved Zepbound® in November 2023 for chronic weight management in adults with initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity — including hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
While tirzepatide was already available as Mounjaro® for type 2 diabetes, the approval of Zepbound® reflects the regulatory recognition of tirzepatide's profound efficacy specifically in the context of obesity management — based on the dedicated SURMOUNT clinical trial program that enrolled over 16,000 participants across four Phase 3 trials.
Zepbound® is identical in formulation and dosing to Mounjaro® — both contain tirzepatide at doses of 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. The distinction lies in their respective FDA-approved indications: Mounjaro® for type 2 diabetes, Zepbound® for weight management. In practice, insurance coverage determinations, prior authorization requirements, and prescribing decisions are tied to these distinct indications.
The mechanism that gives Zepbound® its exceptional efficacy is the dual activation of two incretin receptor pathways — both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor — simultaneously. This "twincretin" approach produces metabolic effects that exceed what either pathway can achieve alone, as demonstrated by comparison data from the SURPASS-2 trial showing tirzepatide outperforming semaglutide 1 mg on both glycemic and weight endpoints.
At its highest doses studied in the SURMOUNT-1 trial, tirzepatide produced an average body weight reduction of approximately 22.5% over 72 weeks — a result that approaches the outcomes seen with bariatric surgery in some studies and substantially exceeds any previously available pharmacological intervention for obesity.
~22.5%
Average body weight reduction at 15 mg dose over 72 weeks
2023
Year of FDA approval for chronic weight management
63%
Of patients at 15 mg achieved ≥20% body weight reduction
Mechanism of Action
How Zepbound® Works
Zepbound® achieves its exceptional weight reduction outcomes by activating two distinct incretin hormone receptor systems simultaneously — a mechanism that distinguishes it fundamentally from all previously approved weight management pharmacotherapies, which targeted single receptor pathways.
The GLP-1 (glucagon-like peptide-1) component of tirzepatide activates GLP-1 receptors in the hypothalamus, gastrointestinal tract, and pancreas. In the hypothalamus, this activation suppresses appetite-regulating circuits that drive hunger and food-seeking behavior — particularly in areas involved in reward processing, where high-calorie foods generate pleasurable signals. Patients on GLP-1 therapy typically report a significant reduction in what is often described as "food noise" — the persistent mental preoccupation with food that makes sustained dietary restriction so difficult. Peripherally, GLP-1 receptor activation slows gastric emptying, extending the period of post-meal satiety, and promotes glucose-dependent insulin secretion while suppressing glucagon.
The GIP (glucose-dependent insulinotropic polypeptide) component activates a second, distinct receptor pathway. GIP receptors are expressed in the pancreas, adipose tissue, bone, and brain. GIP receptor activation in adipose tissue influences fat storage and lipid metabolism; in the pancreas, it augments insulin secretion in a glucose-dependent manner. Importantly, animal and emerging human data suggest that GIP receptor activation in the brain may contribute additional appetite-modulating effects that complement the GLP-1 pathway.
The precise mechanisms underlying the clinical superiority of dual GIP/GLP-1 agonism over single GLP-1 agonism remain an active area of scientific investigation. Current evidence points to the GIP component contributing additional central appetite suppression, enhanced adipose tissue lipid metabolism, and possibly improved overall energy homeostasis beyond what GLP-1 activation alone can achieve.
In clinical practice, the combined effect manifests as profound, sustained appetite reduction with a metabolic environment that favors fat mobilization — producing weight reductions that are, at the highest doses, approaching those seen with surgical interventions in select patient populations.
Dual Incretin Pathway Activation
Simultaneous GIP and GLP-1 receptor agonism produces synergistic effects on appetite suppression, insulin regulation, and fat metabolism that exceed what either pathway achieves alone — the clinical basis of Zepbound®'s exceptional efficacy.
Central Appetite Suppression
Both GLP-1 and GIP receptors in the hypothalamus and reward circuits are activated, profoundly reducing hunger signals and food-seeking behavior. Patients report substantial reduction in appetite and food preoccupation.
Adipose-Specific Metabolic Effects
GIP receptor activity in fat tissue influences lipid storage and mobilization — contributing to the magnitude of fat-mass reduction observed in SURMOUNT trials, where body composition data showed preferential fat mass reduction.
Candidacy
Who May Be a Candidate
Zepbound® is FDA-approved for chronic weight management in adults with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related health condition. Weight-related conditions that qualify under the approved indication include hypertension, type 2 diabetes, dyslipidemia (elevated cholesterol or triglycerides), obstructive sleep apnea, and cardiovascular disease.
The telehealth consultation facilitated by The Project Rx is designed to conduct a thorough evaluation of your eligibility for Zepbound®. Your licensed provider will review your medical history, current medications, metabolic lab values, prior weight management attempts, and health goals to determine whether tirzepatide is clinically appropriate for you. The consultation is the essential first step — and the prescription decision rests entirely with the licensed provider.
An important consideration for patients with type 2 diabetes: if you are already prescribed Mounjaro® for diabetes, adding Zepbound® is not appropriate (they contain the same molecule). Your provider can discuss whether transitioning your existing tirzepatide prescription to a weight-management indication is clinically supported in your situation.
Long-term weight management pharmacotherapy is most effective as part of a comprehensive approach — including dietary modification, physical activity, behavioral support, and regular clinical monitoring. Your provider will discuss realistic expectations and the importance of a holistic management strategy alongside medication.
May Be Appropriate If
- ›Adults with BMI ≥30 kg/m² (obesity)
- ›Adults with BMI ≥27 kg/m² plus hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or cardiovascular disease
- ›Patients who have not achieved adequate weight reduction through lifestyle interventions alone
- ›Adults seeking long-term, medically supervised weight management
- ›No prior serious hypersensitivity reaction to tirzepatide
- ›No personal or family history of medullary thyroid carcinoma or MEN2
Not Typically Appropriate If
- —Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome
- —Current pregnancy or breastfeeding
- —Type 1 diabetes (not indicated)
- —Active pancreatitis or prior history of pancreatitis
- —Already on Mounjaro® (same molecule — cannot combine)
Dosing Overview
Titration Schedule
Zepbound® uses the same titration schedule as Mounjaro® — beginning at 2.5 mg weekly and increasing by 2.5 mg increments every four weeks, up to a maximum of 15 mg weekly. The extended titration schedule (up to 20 weeks to reach maximum dose) reflects the need for gradual GI adaptation and was designed based on the tolerability experience from the Mounjaro® program.
In the SURMOUNT-1 trial, participants were titrated over 20 weeks to the target dose of either 10 mg or 15 mg. The majority of weight reduction occurred after the full dose was reached and maintained — illustrating that patience through the titration phase is rewarded by outcomes at higher doses.
Your prescribing provider will determine your target maintenance dose based on response, tolerability, and clinical goals. For weight management, the 10 mg and 15 mg doses produced the most substantial outcomes in SURMOUNT-1, though meaningful weight reduction was also observed at 5 mg. The decision about whether to continue dose escalation is made collaboratively with your provider based on your progress and your experience of side effects.
Unlike compounded tirzepatide — which has been subject to significant quality and safety concerns — Zepbound® is manufactured by Eli Lilly under FDA-regulated pharmaceutical conditions with rigorous quality control and pharmacovigilance monitoring.
Weeks 1–4
Initiation — GI tolerance phase
2.5 mg/week
Weeks 5–8
Dose escalation
5 mg/week
Weeks 9–12
Continued escalation
7.5 mg/week
Weeks 13–16
First high-dose maintenance option
10 mg/week
Weeks 17–20
Continued escalation if needed
12.5 mg/week
Week 21+
Maximum dose — highest efficacy tier
15 mg/week
* Dose adjustments are determined by your prescribing provider based on response and tolerability. Not all patients advance to higher doses.
Clinical Evidence
What the Research Shows
~22.5%
Average weight reduction at 15 mg dose over 72 weeks
SURMOUNT-1 trial
63%
Achieved ≥20% weight reduction at 15 mg dose
SURMOUNT-1 trial
~$550
Estimated monthly cost without insurance — lower than Wegovy®
Market pricing estimates
The SURMOUNT clinical trial program is the foundation of Zepbound®'s FDA approval and represents the most comprehensive clinical investigation of pharmacological weight management conducted to date. The program enrolled over 16,000 adults across four Phase 3 trials, generating data that substantively redefined the therapeutic potential of pharmacotherapy for obesity.
SURMOUNT-1 — the pivotal efficacy trial — enrolled 2,539 adults with obesity or overweight without type 2 diabetes. Participants randomized to tirzepatide 15 mg lost an average of approximately 22.5% of body weight over 72 weeks, compared to 2.4% with placebo. Critically, 63% of participants in the 15 mg group achieved 20% or greater body weight reduction — approaching outcomes historically associated with bariatric surgery in select populations. At 10 mg, average weight reduction was approximately 21.4%.
SURMOUNT-2 evaluated tirzepatide specifically in adults with type 2 diabetes — demonstrating robust weight reduction even in a population where pharmacological weight management tends to be more difficult, with average reductions of approximately 15% at the 15 mg dose.
SURMOUNT-3 incorporated an intensive lifestyle intervention run-in phase before randomization, then compared tirzepatide versus placebo among those who achieved initial weight reduction — demonstrating further meaningful weight loss with tirzepatide even in patients who had already reduced weight through intensive lifestyle changes.
SURMOUNT-4 assessed discontinuation effects, confirming — as seen with other weight management medications — that weight regain follows treatment discontinuation, reinforcing the understanding of obesity as a chronic condition requiring sustained management.
Safety Information
Side Effects & Risks
The tolerability profile of Zepbound® mirrors that established in the Mounjaro® program — gastrointestinal side effects are the most common, predominantly during dose escalation. In the SURMOUNT-1 trial, approximately 37% of participants in the 15 mg group reported nausea compared to 9% with placebo. Diarrhea (22% vs. 8%) and vomiting (15% vs. 3%) were also more frequent in the tirzepatide group. The majority of GI events were mild to moderate, and most occurred during the initial weeks of each dose escalation.
Discontinuation due to side effects was reported in approximately 7% of participants on tirzepatide in SURMOUNT-1 — meaning over 90% of patients were able to continue treatment through the 72-week trial period. For those who find the standard escalation schedule too fast, providers can extend the time at intermediate doses to improve tolerability.
The 20-week titration schedule for Zepbound® — longer than Wegovy®'s 16-week schedule — reflects the learnings from Mounjaro® about managing tolerability at higher doses. Patience during the titration period is important: the most pronounced clinical benefits are observed once patients reach and maintain the 10–15 mg dose range.
Common (≥1 in 10)
- · Nausea (most common — peaks during dose escalation, often diminishes)
- · Diarrhea
- · Vomiting
- · Decreased appetite (expected and part of mechanism)
- · Constipation
- · Abdominal pain / discomfort
- · Dyspepsia
- · Injection site reactions (mild, typically transient)
Serious Risks (Discuss with Provider)
- · Pancreatitis (black box warning — discontinue if suspected)
- · Thyroid C-cell tumors (contraindicated in MTC/MEN2 history)
- · Hypoglycemia (risk elevated when combined with insulin or sulfonylureas)
- · Gallbladder disease (cholecystitis / cholelithiasis — especially with rapid weight loss)
- · Acute kidney injury (dehydration from GI side effects)
- · Serious hypersensitivity / anaphylaxis (rare)
- · Suicidal ideation / self-harm (post-market monitoring; report mood changes)
Zepbound® carries a black box warning regarding the risk of thyroid C-cell tumors observed in animal studies. While human causation has not been established, the medication is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients should not use Zepbound® concurrently with Mounjaro® or any other GLP-1 or GIP/GLP-1 agent. Always review the complete FDA prescribing information with your licensed provider before initiating treatment.
How It Works
The Consultation Process
The Project Rx facilitates access to licensed telehealth consultations through LegUp Health, a network of licensed providers with expertise in metabolic health and weight management. Our partner platform is HIPAA-compliant and designed for the clinical rigor that prescription weight management medications require.
For patients prescribed Zepbound®, ongoing monitoring is an essential component of safe, effective treatment. The telehealth model enables regular provider access — important for managing dose titration, monitoring metabolic response, and addressing side effects as they arise. Below is the typical consultation and treatment journey.
Complete the Health Intake
Provide a comprehensive health history including your weight history, prior weight management attempts, current medications, metabolic labs, and comorbidities. This information is reviewed by a licensed provider before your consultation.
Telehealth Consultation
A licensed provider evaluates your candidacy for Zepbound® based on your intake, clinical history, and BMI/comorbidity profile. The dual GIP/GLP-1 mechanism, expected outcomes, and management plan are discussed.
Baseline Lab Evaluation
Labs including metabolic panel, HbA1c, thyroid panel, lipids, and kidney function are reviewed or ordered to establish baseline values and screen for contraindications.
Prescription & Savings Programs
Clinically eligible patients receive a prescription for Zepbound® through a licensed pharmacy. Insurance prior authorization support and Eli Lilly savings program information are provided to minimize out-of-pocket costs.
Ongoing Monitoring
Regular follow-up consultations, dose adjustments based on titration schedule and tolerability, and metabolic monitoring are maintained throughout your treatment. Provider access is available between scheduled visits for urgent questions.
What to Expect
Month-by-Month Overview
Zepbound® produces its most significant weight reduction outcomes at higher doses, reached after 20 weeks of titration. This means patience during the escalation phase is rewarded — the most substantial clinical benefits typically emerge in months 5 through 12 and beyond for patients who reach and maintain the 10–15 mg dose range.
The SURMOUNT-1 trial tracked participants for 72 weeks — approximately 17 months — and the average weight reduction curve continued to slope downward for most of that period before beginning to plateau. This is a longer active reduction window than most patients expect, and it underscores that Zepbound® is a long-term management tool, not a short-term intervention.
Titration Phase
Gradual dose escalation from 2.5 mg to target dose. GI adjustment period — most pronounced around dose transitions. Some early appetite changes common. Weight changes vary at this stage; focus is on tolerability and adherence.
Full Dose Established
At 10 or 15 mg maintenance, appetite suppression is typically at its most pronounced. Food noise reduction is often described as dramatic by patients at this stage. Weight reduction is often accelerating. Metabolic markers begin improving measurably.
Progressive Reduction
Continued weight reduction. In SURMOUNT-1, the weight loss curve continued declining through 52–60 weeks for most participants. Physical activity typically becomes more accessible as weight decreases. Improvements in blood pressure, lipids, and glycemic markers are common.
Plateau & Maintenance
Weight reduction plateaus as a new physiological equilibrium is approached. SURMOUNT-1 participants at 72 weeks had achieved and largely maintained their peak weight reductions. SURMOUNT-4 confirms that discontinuation leads to regain — ongoing treatment supports maintenance.
FAQ
Frequently Asked Questions
Access & Pricing
Starting at $550/month
Medication cost is an estimate based on current market pricing. Zepbound® is generally priced lower than Wegovy® and has been expanding insurance coverage as obesity pharmacotherapy gains broader recognition. Eli Lilly offers savings programs for eligible patients.
Begin Your ConsultationEligibility is determined by a licensed provider following your consultation. Not all patients qualify for a prescription.
Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. The Project Rx is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. Brand names appearing on this page are used solely for informational identification of the referenced medications. The Project Rx facilitates access to licensed telehealth consultations; we do not manufacture, sell, or dispense prescription medications. All prescription decisions are made exclusively by licensed medical professionals following a clinical evaluation. This content is for informational purposes only and does not constitute medical advice. Individual results vary. Not all patients who complete a consultation will receive a prescription.